Introduction and Objective: While β cell dysfunction represents a key pathogenetic factor in T2D onset, collecting appropriate pancreatic samples from metabolically profiled donors has proven challenging. In this study, we investigate possible mirroring between in vivo insulin secretion and ex vivo islet function of subjects with and without T2D.Methods: 36 subjects in list for pancreatectomy […]
Read MoreMonth: June 2025
173-OR: Eligibility, Impact, and Costs for Tirzepatide for the Primary Prevention of Diabetes Mellitus
Introduction and Objective: A recent trial of tirzepatide (SURMOUNT) found a 92% reduction of diabetes incidence among patients with overweight or obesity over three years. Our objective was to estimate the potential population, outcomes, and cost associated with use of tirzepatide for the primary prevention of DM.Methods: Data from the 2021-2023 cycle of the National […]
Read More291-OR: Effect of Type 2 Diabetes Characteristics on Semaglutide Treatment in People with Type 2 Diabetes and Peripheral Artery Disease—A Post Hoc Analysis of the STRIDE Trial
Introduction and Objective: The STRIDE trial (NCT04560998) demonstrated that once weekly semaglutide 1.0 mg significantly improved maximum walking distance (MWD) in people with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD) vs. placebo. Whether the benefits are consistent across T2D characteristics has not been described.Methods: The primary outcome in STRIDE, MWD measured on […]
Read More292-OR: Oral Semaglutide and Cardiovascular Outcomes by Baseline A1C and BMI in People with Type 2 Diabetes in the SOUL Trial
Introduction and Objective: In SOUL (NCT03914326), oral semaglutide (sema) 14 mg QD, a GLP-1 receptor agonist, reduced major adverse cardiovascular (CV) event (MACE) risk by 14%. GLP-1RAs are routinely prescribed to reduce A1c and BMI in type 2 diabetes (T2D). Whether the CV benefits of oral sema are influenced by baseline A1c or BMI is […]
Read More297-OR: Interactive Virtual Assistant for Health Promotion and Diabetes Care in Older Adults with Diabetes—A Randomized Controlled Trial
Introduction and Objective: This study evaluated the impact of an interactive virtual assistant device, programmed with a behavioral intervention model, on mental-health and diabetes-related outcomes in older adults with type 2 diabetes (T2D)Methods: We conducted a randomized controlled trial enrolling participants aged 65 years or older with T2D. Participants were randomized to receive a Smart […]
Read More
CDC Votes Against Flu Shots With Thimerosal: What to Know
Share on PinterestThimerosal, a mercury-containing preservative, has been in vaccines and other drugs since the 1930s. VioletaStoimenova/Getty Images A CDC advisory panel voted 5–1 to recommend only flu vaccines without the preservative thimerosal. Thimerosal is a mercury-containing compound used as a preservative in vaccines and other drugs. Doctors and physician advocacy groups warn that the […]
Read More
Black Coffee Without Cream, Sugar May Lower Death Risk
Share on PinterestDrinking coffee black without cream or sugar could help reduce your risk of death from cardiovascular disease. Getty Images/Kseniya Ovchinnikova Researchers say daily coffee consumption can lower a person’s overall mortality risk as well as their risk of death from cardiovascular disease. However, the benefits decline for those who add significant amounts of […]
Read More
Can GLP-1 Drugs Actually Make Your Penis Larger?
Share on PinterestA growing number of males on Reddit are claiming that GLP-1 drugs have increased their penis size. Kupicoo/Getty Images Male Reddit users are reporting what they call “Ozempic penis,” with some claiming penile growth of up to 1.5 inches. Experts say, however, that Ozempic penis is not a true side effect of GLP-1 […]
Read More
FDA Approves Highly Effective, Twice-Yearly Shot for Prevention
Share on PinterestYeztugo is a twice-yearly injection to prevent HIV that could improve adherence rates compared to other PrEP medications. d3sign/Getty Images The FDA has approved lenacapvir, a twice-yearly injection to prevent HIV infection that could improve adherence rates compared to other PrEP medications. The drug, which will be sold under the brand name Yeztugo, […]
Read More
Fasting plasma glucose outperformed 1-hour plasma glucose in predicting diabetes incidence in individuals with family history of young-onset type 2 diabetes
Results From the original cohort of 477 siblings in the HKFDS and 863 presumably unrelated individuals in the BHBHK, 583 individuals were included in the present analysis, of whom 235 individuals from 104 families had a FmH-YOD and 348 unrelated individuals reported no FmH of diabetes (FmH-NONE) (figure 1 and online supplemental figure 1). In […]
Read More